soul trial oral semaglutide cardiovascular outcomes results 2025 nejm Cuts Risk by 14% in soul trial oral semaglutide cardiovascular

97 LiY.ShanX.GaoR.HanT.ZhangJ.WangY.et al

10.1111/prd.12002 43 CeremugaM.StelaM.JanikE.GorniakL.SynowiecE.SliwinskiT.et al (2020)

Endocrinology 156 (7), 24172428

A 2018 meta-analysis published in Diabetes Care pooled GLP-1 agonist trial data and found no significant increase in pancreatitis risk (relative risk 0.93 to 95% CI 0.65-1.34)

Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushings disease before and after surgical cure

Drug interactions and lifestyle factors at higher doses At 50 units (particularly at higher concentrations where the mg dose is significant), interactions with other substances and lifestyle factors become more relevant